OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-09-30-accounts

Orchid Cancer Appeal Annual report and financial statements 2024-2025

Orchid Cancer Appeal Annual report and financial statements 2024-2025

Board of Trustees

Mr W Cohen Treasurer Mr D Badenoch

Mr J Shedden

Mr PG Bracher (resigned 14 April 2025)

Mr S Harris (resigned 14 April 2025)

Mr CS Osborne (resigned 14 April 2025)

Professor RTD Oliver (resigned 24 January 2025)

Mr B Ayres (resigned 14 April 2025)

Professor P Rajan (resigned 13 April 2025)

Mr M Bryan-Brown (appointed 4 December 2024, resigned 14 April 2025)

Dr J Reddy (appointed 4 December 2024, resigned 14 April 2025)

Chief Executive Mr A Orhan

Independent Examiner

Moore Kingston Smith LLP 6th Floor, 9 Appold Street, London EC2A 2AP

Accountants JS2 Limited 1 Crown Square, Woking, Surrey GU21 6HR

Legal advisors Farrer & Co 66 Lincoln’s Inn Fields, London WC2A 3LH

Bankers HSBC Plc 1 Centenary Square, Birmingham B1 1HQ

Registered Office 60 Gray’s Inn Road, London WC1X 8AQ

Tel 020 3745 7310 www.orchid-cancer.co.uk

Honorary Presidents

Professor RTD Oliver (appointed 14 April 2025)

Mr CS Osborne (appointed 14 April 2025)

Registered in England with the Charity Commission No.1080540

Company Limited by Guarantee Registered in England No. 03963360

Orchid is an award-winning charity dedicated to supporting the needs of those affected by male cancers. We fund pioneering research, raise awareness and deliver vital services to those affected by penile, testicular or prostate cancer. Here’s how we made a positive difference during the past year...

Welcome from the Trustees 6 Letter from the CEO 8 The year in review 10 Fundraising 16 Prostate cancer 18 Testicular cancer 22 Penile cancer 26 Research 30 The year ahead 36 Governance 40 Financial review 44

Welcome from Orchid’s Trustees

We are pleased to present Orchid’s Annual Report and Accounts for the period 1 October 2024 to 30 September 2025. This document showcases the considerable achievements made in our fight against prostate, testicular and penile cancers, whilst also outlining the challenges encountered during the year, and the actions taken by the Board in response.

Enhancing public understanding of male cancer risk factors and potential early warning signs remained a central focus. Our small, dedicated team employed innovative approaches to deliver vital male cancer messaging to both men and women across the four nations. The provision of information and support via our unique Nurse-led services assumed even greater importance as the incidence of male cancers continues to rise. Each year, more than 58,000 men in the UK receive a diagnosis of prostate, testicular or penile cancer.

During the year, we were pleased to support two important research initiatives: the Robert Lane Tissue Bank which is committed to translating basic research into practical treatments for patients, and a

research project which explored the role of anaerobic bacteria in the aggressiveness of prostate cancer.

The charity continued to be led by Ali Orhan, who, in addition to serving as CEO, also acts as the Director of the Active Participation in Male Cancer Awareness in Prisons programme funded by the National Lottery Community Fund.

Despite the dedicated efforts of the team, generating income – particularly unrestricted funding – became more challenging as the year progressed. In response, and with the long-term sustainability of the charity in mind, Trustees introduced a number of cost-management measures part way through the year. These included a careful reshaping of the staff team and the temporary pausing of research funding, to ensure that we could continue to prioritise support for those who rely on our services.

Trustees also conducted a comprehensive governance review using the template of the Charity Governance Code and the Charity Commission's governance recommendations. As a result, the Board underwent a planned consolidation, reducing its size to a focused group of Trustees to steer Orchid through the latter period of the year and beyond.

We ended the year in a strong and stable position, and we are now looking at how we regrow the

6

Testicular cancer Penile cancer Research The year ahead Governance Financial review

We ended the year in a strong and stable

position, and we are now looking at how we regrow the charity.

charity. We will also ensure that the Board reflects the needs of the charity.

We extend our gratitude to past Trustees who contributed to the governance review, and to those who stepped down during the process. Their service and dedication are deeply appreciated.

We were also pleased that founding Trustees Colin Osborne CBE and Professor Tim Oliver accepted our invitation to become Honorary Presidents recognising their exceptional contributions to Orchid’s work.

As we look ahead, our commitment to saving men’s lives from prostate, testicular and penile cancer remains unwavering.

Our achievements would not be possible without the generosity of our supporters, the dedication, passion and drive of our staff team, and the tireless efforts of our volunteers.

Thank you to everyone who helped and supported us in the past year and who continues to do so in the new financial year. Our progress is possible only through your ongoing engagement and support.

Orchid Trustees

7

Letter from the CEO

Dear Supporters, Partners and Friends

The year 2024–2025 has been one of challenge, reflection, and resilience for Orchid.

Like many charities operating in an increasingly uncertain economic climate, we faced significant financial pressures, rising service demand, and difficult operational decisions. However, I am immensely proud to say that we responded not by retreating, but by adapting. We resized, restructured, and refocused always guided by one clear priority: ensuring that men and their families continued to receive trusted, specialist support when they needed it most.

Charles III and Queen Camilla in recognition of community-based cancer support organisations.

To stand among peers from across the cancer community, acknowledged for the work we collectively do to support patients and families, was both humbling and energising. It was not simply a ceremonial occasion it was recognition of the impact that grassroots, patient-focused charities like Orchid make every single day.

This invitation belonged not just to Orchid as an organisation, but to every supporter, volunteer, donor, trustee, clinician, and service user who contributes to our mission.

Throughout this period of change, we maintained our core services. Our nurse-led helpline continued to provide confidential, evidence-based information and reassurance. Our educational outreach remained active across communities, workplaces, and healthcare settings. Our digital resources expanded their reach, ensuring that accessible, accurate information about prostate, testicular, and penile cancer remained available to all.

Resilience is not simply about survival it is about purpose. And our purpose has never been clearer.

During the year, we undertook necessary organisational adjustments to ensure long-term sustainability. These included:

While change is never easy, these measures have positioned Orchid to remain stable, focused, and impact-driven in the years ahead.

One of the most significant highlights of the year was being invited to a reception hosted by King

I would also like to extend my heartfelt thanks to everyone who responded to our emergency appeal

8

Testicular cancer Penile cancer Research The year ahead Governance Financial review

Your response to our emergency appeal was deeply moving, and reaffirmed something powerful: Orchid is not just an organisation, it is a community.

during this challenging period. The generosity, speed, and belief shown by our supporters at a time of real need was deeply moving. Your contributions helped us protect vital services and continue delivering specialist support without interruption. That response reaffirmed something powerful: Orchid is not just an organisation it is a community.

Our reach continues to grow beyond the UK. Orchid’s work now extends across Europe through collaborative awareness initiatives and shared educational resources. The penile cancer animation we were proud to help develop for the European Association of Urology (EAU) continues to receive thousands of views, reaching new audiences and breaking down stigma around a disease that remains under-discussed and often misunderstood. Its continued engagement demonstrates the importance of bold, accessible, and patient-focused communication in driving earlier conversations and, ultimately, earlier diagnosis.

Demand for our services remains high. Conversations around male cancer are increasing yet stigma and late presentation persist. Our role in ensuring men have somewhere to turn for accurate information and compassionate support remains critical.

As we move forward, our commitment remains unwavering:

The year tested us, but it also reaffirmed the strength of our community.

On behalf of the Board of Trustees and the entire Orchid team, I extend my sincere thanks to everyone who has supported us throughout this period. Your trust enables us to continue this vital work.

Together, we will ensure that no man faces cancer alone.

With gratitude,

Ali Orhan

Chief Executive Officer

9

The year in review 1 October 2024 to 30 September 2025

We were proud that our continued efforts in raising awareness and supporting men affected by prostate, testicular or penile cancer and their families were recognised with an invitation to attend a Royal Reception at Buckingham Palace, hosted by His Majesty The King and Her Majesty The Queen.

The attendance at this inspirational event in April by a small group of our staff team, a long-term supporter, and representatives of partner charities, was a powerful testament to the unwavering dedication of our team, volunteers, and supporters who work tirelessly to advance our mission.

Orchid’s work is more important than ever as the number of people diagnosed with prostate, testicular or penile cancer each year in the UK is increasing. Furthermore, men diagnosed with one of these cancers can undergo a wide range of emotions including from shock to sadness to worrying about the future. There are now over

58,000 new cases of these three male-specific cancers each year. Yet despite rising cases, there is

Accurate information about penile cancer is hard to find. Around 70% of calls to our helpline related to this rare cancer.

low male cancer awareness, and too many men are diagnosed with late-stage disease, and more than 12,000 lives are lost to these cancers each year.

Throughout the year, we provided information on risk factors, potential symptoms and the importance of early detection to men and women across the UK, complemented by our Nurse-led services . We also gave funding towards two research projects to advance understanding and treatment of male cancers.

Orchid’s freephone confidential Male Cancer helpline was open for five days a week throughout the year and our two Male Cancer Nurse Specialists were on hand to support callers from 9am to 5.30pm Monday to Friday. Accurate information about penile cancer is hard to find, and during the year, around 70% of calls related to this rare cancer.

10

Testicular cancer Penile cancer Research The year ahead Governance Financial review

Orchid Nurse Rob Cornes continued to support one of the UK’s largest testicular cancer support groups throughout the year. In response to expressed

needs, two new online support groups were set up and run by Orchid. One was for the wives and partners of those diagnosed with penile cancer, and the other was for the men themselves. Those attending acknowledged the benefits of peer support and the chance to talk openly about their worries and concerns in a safe space.

Orchid continued to offer our unique telephone counselling service for men diagnosed with the rare testicular or penile cancer and who live anywhere in the UK. At the request of wives and partners of those diagnosed with penile cancer, this service was extended to include them. Nurses on the Helpline assessed callers’ needs, and where relevant, men and wives and partners were referred to this unique service. Evaluation remains positive.

As well as supporting patients, Orchid Nurse Rob Cornes worked with other healthcare professionals. One example is that he attended the National Germ

Where captured from callers to our Helpline:

Cell Conference , a biannual conference which brings together urologists, oncologists and specialist nurses who are involved in the care and treatment of testicular cancer patients. As part of the Testicular Cancer Network, Rob took part in an active roundtable discussing the benefits of peer support on physical and psychological well-being.

5,947

men, women and healthcare professionals had in-depth support or information directly from an Orchid Nurse or Male Cancer Information Manager.

119

sessions from Orchid's testicular and penile cancer counselling service benefitted 20 people.

170

targeted awareness and support activities were delivered across the UK.

77

Male Cancer Volunteer Champions in prisons in England were trained by Orchid.

11

Early detection can save lives which is why male cancer education remained a priority during the year. Day long Male Cancer Information Roadshows were delivered in the heart of targeted communities and provided 7,920 people – an increase of over 200 on the previous year – with the opportunity to learn about male cancers and talk about any concerns.

Of those who responded to monitoring at Orchid Roadshows:

We also delivered Health at Work talks throughout the year, both in person and online, and our dedicated team of Community Champions in Nottingham continued to cascade prostate cancer messages throughout the city. Improved evaluation of our education and awareness activities has been introduced across all activities. We now measure increased knowledge, the confidence to seek help or to help someone seek help, and the confidence to share male cancer knowledge with others.

Of those who responded to monitoring at Health at Work talks:

Our Roadshows provided the opportunity to learn about male cancer and talk about concerns for 7,920 people – an increase of over 200 on the previous year

12

Testicular cancer Penile cancer Research The year ahead Governance Financial review

Our ‘male cancer doesn’t

discriminate’ social media

campaign reached almost a million accounts

Social media and digital activity played a huge role in educating people about male cancers and the bespoke support services Orchid can offer. It also enabled us to reach new audiences. One campaign targeted deaf people who often miss mainstream health education. Posts carried the strapline “Male cancer doesn’t discriminate.” Through both paid advertising and our own social media channels we reached 990,890 accounts. Very positively, there were 9,180 post saves. Another campaign delivered during April’s Testicular Awareness Month aimed to break down stigma and to promote early detection of testicular cancer, especially in deprived urban communities. The campaign featured

Orchid reached 289,460

accounts through our

Facebook, X, Instagram,

TikTok and LinkedIn

platforms.

a young man with lived experience of testicular cancer, as well posts themed “Not all spring growths are good.” Using a mix of paid advertising and our own social media channels, Orchid reached over 880,000 accounts. There were more than 53,000 interactions evidencing interest in the content.

Both Orchid’s Male Cancer Awareness Week in September 2025 with the theme of early detection, and International Penile Cancer Awareness Day on September 20th for which Orchid leads, were delivered digitally.

Alongside our core activities, Orchid delivered targeted projects and activities throughout the year. The most far reaching of these was the delivery of the first full year of the three-year programme funded by the National Lottery Community Fund entitled “Active participation in male cancer awareness in prisons in England” . Orchid is passionate about reducing health disparities and promoting equitable access to vital health information for everyone, and people in prison are one of the most deprived groups in society. They miss mainstream health messaging, and many prison residents have low health literacy.

Delivered by Project Director, Ali Orhan, and Project Manager, Julia De Petrillo, this important project, which began just ahead of the reporting year, is taking prostate, testicular and penile cancer messages into all male prisons in England.

13

91,193

pieces of specialist information were disseminated through targeted awareness activities such as Roadshows, our Active Participation in Prisons project, Orchid’s Four Nations Penile Cancer project, our Volunteer Community Champions, talks and presentations.

Working mainly with prison healthcare teams, the programme is being delivered flexibly with a choice of activities to suit different settings. The most popular options chosen by prisons over the year were an in person visit from Ali Orhan to train Male Cancer Volunteer Community Champions, to deliver a workshop or talk for residents, or to attend a health fair. We trained healthcare teams in prisons as well as the wider staff team to help them better understand male cancers.

Every prison resident is provided with a resource with information about each of the male cancers. This was developed in consultation with prison residents and staff and is in the form of a bookmark. Also, a short film is available to those with access to Wayout TV which provides prisoners with educational and rehabilitative content in their cells.

Throughout the year Orchid’s Four Nations Penile Cancer Programme was led by Male Cancer Nurse Specialist Sinéad Collins. This continued to address the lack of awareness of this rare cancer even

amongst healthcare professionals, as well as helped men and their wives and partners cope with the impact of a diagnosis. Sinéad also worked with Orchid Nurse Rob Cornes on a GP learning module about the diagnosis and referral of penile cancer. More information about the considerable achievements of Orchid’s two-year Four Nations Penile Cancer programme can be found in the penile cancer section of this report.

Diversity and inclusion are at the heart of all we do. We completed the delivery of our Prostate Cancer and Faith project , developed in response to Black men’s increased risk of prostate cancer, and which targeted Black African and Black Caribbean faith leaders and congregations in both Birmingham and London.

Work began on a new project called Awareness Within Faith , which was designed to address critical disparities in male cancer outcomes and HPV vaccine uptake among diverse communities across London. HPV is a significant risk factor for the rare penile cancer.

Resources on the Orchid website became downloadable only during the year. This cost saving approach ensures people can still access information whilst directing funds towards our services.

Page views on the Orchid website increased to

85,050

with a further 18,000 page views on Your Privates, our testicular cancer microsite.

14

Testicular cancer Penile cancer Research The year ahead Governance Financial review

All Orchid information is subject to regular reviews to ensure it contains the most uptodate, accurate and accessible information to meet the needs of men.

Some information was updated during the year; and a new series of fact sheets about each of the male cancers was added to the portfolio.

with the European Association of Urology (EAU) and the European Reference Network for Rare Urogenital Diseases (eUROGEN). As the only male cancer charity in Europe with membership of these influential networks, we are proud that Orchid continued to help shape the future of care for the rare penile and testicular cancers.

One example of our involvement is that Orchid Nurse Rob Cornes, as the advocate for penile and testicular cancer, took part in the EAU Patient

Advocacy meetings alongside urologists, patient advocates and organisations from all over Europe. The aim of the group is to create information and resources which will improve the journey for anyone affected by a urological condition including cancer and will benefit patients including in the UK.

Orchid’s work could not happen without the generosity and commitment of our supporters and volunteers. It is thanks to the support of individuals, community and faith groups, the National Lottery Community Fund, Charitable Trusts and Foundations and our corporate supporters that we were able to deliver our Nurse-led services, targeted programmes and to have funded vital research in the reporting year. We are grateful to everyone who helped in any way.

A video about prostate cancer in trans women

was also filmed to highlight the fact that prostate cancer is not just a “men’s health issue.” People who were registered male at birth, including many trans women and non-binary people, still have a prostate unless it has been surgically removed, and can develop prostate cancer.

Orchid’s position as a key patient advocacy organisation within the European urological

landscape was further strengthened during the year through our continued and active role in collaboration

15

Fundraising

Orchid is committed to fundraising from diverse income streams to spread risk, to provide greater financial stability, and to ensure the charity can continue our operations which benefit those at risk of or diagnosed with prostate, testicular or penile cancer.

A total of £729,636 was raised during the year which was slightly below the previous year’s income reflecting the difficult fundraising environment and the challenges Orchid, like so many charities, faced in generating funds.

At the beginning of the year, we undertook a deep dive into all our fundraising activities, and as the year progressed it became particularly difficult to secure unrestricted funds. Trustees reviewed both income and expenditure which resulted in a resizing of the fundraising team whilst still balancing a mix of income sources. July saw the launch of Orchid’s first ever Emergency Appeal entitled “Don’t let men face cancer alone” to which our supporters responded very positively, and which raised £28,361 providing a much need injection of funds.

Despite the challenges of the year, we feel truly humbled by the tireless dedication and generosity of our fundraisers and supporters. We offer heartfelt thanks to every donor be they an individual, a community group, a sports clubs or school, a Company, a Charitable Trust or Foundation, or The National Lottery Community Fund.

Many Orchid supporters have a connection to our cause, perhaps because they, or someone they know, have been touched by male cancer. People pay tribute to loved ones by giving in their memory, or by leaving a gift in their will. The many wonderful fundraising activities in the last year included fundraising events in schools; challenge and sporting events such as a beach walk, a sea swim, a zip wire challenge, a rugby game and a football match; running events in locations such as Helsinki, Berlin, London and Nottingham; individual challenges such as a 300 mile run and series of runs and ultra marathons; and the annual Twyford Beer Festival.

16

Testicular cancer Penile cancer Research The year ahead Governance Financial review

Despite the challenges of the year, we feel truly humbled by the tireless dedication and generosity of our fundraisers and supporters. We offer heartfelt thanks to every donor.

Orchid continually strives to meet and maintain high standards in all areas of fundraising and recognises the importance of listening to and putting supporters at the centre of everything that we do. We are registered with the Fundraising Regulator and adhere to the Code of Fundraising Practice when carrying out our activities. As the year drew to a close, our small team reviewed the updated Code of Fundraising Practice to ensure all our activities complied with the new Code before it came into effect on 1 November 2025. Our staff are committed to following codes of good practice and standards developed by the fundraising community through the work of the Chartered Institute of Fundraising and other professional bodies.

As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with any external agencies we engage to help us or who raise funds for the Charity. We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries out their activities with the same high standards and care we would ourselves.

Orchid operates a clear and stringent complaints handling procedure that is reported to senior management and the Board of Trustees. During the year we received six complaints in relation to our fundraising activities which were resolved swiftly in line with our procedures. We remain committed to improving our practice, learning from supporter feedback.

We are keen to support those who fundraise on our behalf, and our small team cheered on runners at the London Marathon and the London Landmarks Half Marathon.

We were also delighted to accept an invitation to talk about Orchid’s work at the AGM of long-term supporter the Isle of Man Anti-Cancer Association, and to thank their committee and members for their support. When we cannot be there in person, we encourage and support groups and individuals in other ways.

Grants from Charitable Trusts and Companies, including Pharmaceutical Companies, allowed Orchid to provide information and support to those affected by a male-specific cancer, and to deliver innovative awareness activities. The three-year grant from The National Lottery Community Fund enables the ongoing delivery of the “Active Male Cancer Awareness in Prisons in England” programme, and a grant from the National Lottery Awards for All England funded the development and performance of the play Prostate not Prostrate: When Silence Is the Real Thief. Partnership agreements are in place where needed. We enjoy reporting back to funders to show the impact of their funding and in line with their reporting requirements.

We were delighted to be chosen as a beneficiary of the Rontec Pennies scheme through which customers at Rontec garages across the country rounded up their payments to support Orchid. Furthermore, we were very grateful to receive two legacies in the year.

17

The advice and support I received encouraged me to make the call and get checked out. I’m glad I did. With the early diagnosis, I am now looking at more treatment options and a potentially more positive outcome. Thank you Orchid.

Testicular cancer Penile cancer Research The year ahead Governance Financial review

Prostate cancer

using creativity, drama and humour to drive home some vital messaging.

Welcome from the Trustees CEO’s letter The year in review Fundraising Prostate cancer

Prostate cancer continues to be the

most common cancer in men in the UK with an annual incidence of over 55,000. Sadly around 12,000 men will die from the disease each year, a level which has remained stable over the last five years suggesting an improvement in overall mortality. However, up to 25% of men are diagnosed with late-stage disease.

The incidence for men of Black African and Black Caribbean descent remains twice that of Caucasian men along with family history in a first degree relative and a family history of the BRCA gene responsible for genetic breast cancer.

Orchid continues to engage with men from these high-risk communities. Debate around UK screening programmes continues, and various trials/research initiatives have been launched to identify the most relevant way forward although it is still likely to be a few years before agreement is reached.

Active surveillance continues to be the preferred option for men with low grade prostate cancer while different approaches to more advanced but curable disease are being evaluated for less invasive (focal) treatments.

With over 110 prostate cancer support groups now existing in the UK, face to face and virtual peer support for those diagnosed continues to grow, while many celebrities who have been affected by the disease, talk freely about their experience which serves to promote awareness of the disease alongside the awareness activities delivered by charities such as Orchid.

Orchid is working with the European Association of Urology (EAU), on BALANCE, an international long-term Quality of Life study into the experience of Black African and Black Caribbean men with prostate cancer.

20

Testicular cancer Penile cancer Research The year ahead Governance Financial review

Don’t mess with Patty Dumplin!

Orchid received funding from National Lottery Awards for All England to create an accessible play to raise awareness of prostate cancer amongst Nottingham’s Black African and Black Caribbean community.

To do this, Orchid was delighted to collaborate with Nottingham-based Lisa Jackson of Mon0lisa Productions and the team of Orchid-trained Community Champions who have been cascading prostate cancer messages locally for almost five years.

Audience feedback praised the play’s engaging and informative approach, with viewers committing to sharing the information and to having a conversation with their GP. The many comments made evidence just how well the play achieves its aim of delivering prostate cancer information in an accessible way and starting conversations amongst both men and women.

A performance for men in a local prison is planned, and funding is being sought to take the play to wider audiences across the country.

The play – Prostate Not Prostrate: When Silence Is the Real Thief – draws on the lived experience of the Community Champions and highlights how disproportionately prostate cancer affects Black men. Blending humour with clear impactful messaging, it follows Patty Dumplin as she encourages her husband to undergo a simple but vital health check.

The production premiered to a full audience at the Nottingham Contemporary and was followed by a discussion led by Orchid’s CEO Ali Orhan and the local Community Champions.

Patty also appeared on Nottingham’s urban radio station 97.5 Kemet FM, taking the play’s humour and serious prostate cancer messaging to listeners across the city and surrounding areas.

21

Health information usually

passes me by. Like a lot of blokes I just tend to ignore it. The way Orchid gets information out there is different. They have real people who talk to you. Some of them have even been through it themselves.

And that really hits home.

Testicular cancer Penile cancer Research The year ahead Governance Financial review

Testicular cancer

and our telephone counselling service is unique.

Welcome from the Trustees CEO’s letter The year in review Fundraising Prostate cancer

Testicular cancer in the UK affects around 2,400 men a year. Approximately 70% of these men will be between the ages of 15-45, although it can occur at any age. The incidence and mortality (around 65 men die each year), have remained stable and constant over the last 5 years in the UK.

Testicular cancer also remains the most treatable and potentially curable cancer with 95% of men, including those with metastatic disease, surviving for 10 years. However, it is important to recognise that to achieve cure men may need to undergo gruelling chemotherapy treatment which will have long term survival implications.

Chemotherapy increases the risk of physical illness such as cardiovascular disease, can reduce testosterone levels which may contribute to metabolic syndrome, and can cause temporary, but sometimes permanent side effects, such as poor cognitive function, peripheral neuropathy, and reduced lung function. In addition, the psychological impact of the disease on a predominantly young, less mature age group can often result in severe coping difficulties.

Orchid offered a unique telephone counselling service during the year which allowed men to undergo counselling with a degree of anonymity at a convenient time and at any point in their treatment journey. In addition, Orchid continues to support one of the few testicular cancer support groups in the UK. This group meets physically in London and virtually. It has an online closed Facebook group with around 350 members. Orchid Male Cancer Information Nurse Specialist, Rob Cornes, continues to act as an administrator for the group.

Orchid is working with the European Association of Urology (EAU), the European Reference Network for Rare Urogenital Disease (eUROGEN) as advocates for testicular cancer along with the Global Society of Rare Genitourinary Tumours, enhancing information and support for the disease globally.

24

Testicular cancer Penile cancer Research The year ahead Governance Financial review

Not all springtime growths are good

In April, Orchid launched a targeted social media awareness campaign for Testicular Cancer Awareness Month. This innovative campaign aimed to reduce stigma, and promote early detection of testicular cancer, particularly in deprived urban communities.

Two animations, centred on the theme of Not all spring time growths are good , were created to show young men how to self-check for any changes in testicular health, as well as to help them recognise the potential signs and symptoms of testicular cancer. Using animations helped to make the campaign relatable and fun, whilst also addressing potential literacy barriers.

As well as the two animations, we produced a short social media reel with the help of a young man who had been diagnosed with a testicular cancer, explaining the importance of why young men should get checked.

The campaign targeted relevant audiences across the major UK cities of London, Glasgow, Cardiff, Belfast, Birmingham, and Manchester. It reached over 880,000 accounts through paid advertising and Orchid’s own channels, generating more than 53,000 interactions.

Based on the reach and interactions, we are confident that the campaign was successful in its aim of breaking down stigma and getting those most at risk to think about and engage with testicular health.

25

----- Start of picture text -----
Welcome from the Trustees CEO’s letter The year in review Fundraising Prostate cancer
It’s the impact on families
that most people don’t
understand. But Orchid
gets it, and they’ve got
the skills to guide you
through the emotional
minefield. Let’s face it,
that’s something most of
us guys need.
26
----- End of picture text -----

Testicular cancer Penile cancer Research The year ahead Governance Financial review

Penile cancer

right across the four nations of the UK.

Welcome from the Trustees CEO’s letter The year in review Fundraising Prostate cancer

Penile cancer will affect 36,000 men globally each year with a risk of 1 in 100,000. In the UK it affects around 760 men each year. In the last few years this means that the incidence has increased by just under 10%.

Despite being the rarest of all male-specific cancers, it will often cause the most severe physical and psychological side effects because all curative treatment will involve some form of surgery to the penis itself.

One of the biggest problems is lack of awareness amongst the public and some healthcare professionals. This can result in inappropriate treatment and therefore a delay in diagnosis increasing the risk of more invasive surgery. Although men diagnosed with penile cancer are treated at regional specialist centres, there remains an inconsistency in support. Many men may feel isolated and face difficulty in managing the physical and psychological impact of the disease.

Orchid’s 4 Nations Penile Cancer Programme led by Orchid Nurse Sinéad Collins continued to address these issues throughout the year. Furthermore, Orchid’s website now includes practical information on how to deal with some of these issues, while men as well as their wives and partners benefited from Orchid’s unique and invaluable telephone counselling service as well as from Orchid peer support opportunities.

Orchid gained increasing recognition on a European level for the initiatives we are leading and the support that we are offering. Orchid is working with the European Association of Urology (EAU), the European Reference Network for Rare Urogenital Disease (eUROGEN) as advocates for penile cancer along with the Global Society of Rare Genitourinary Tumours, enhancing information and support for the disease globally.

28

Testicular cancer Penile cancer Research The year ahead Governance Financial review

Orchid’s 4 Nations Penile Cancer Programme

Orchid is grateful to Urology Cancer Nurse Sinéad Collins for her commitment and passion in leading this innovative programme for its two-year duration. The programme enabled Orchid to deliver dedicated awareness and education activities across England, Scotland, Wales, and Northern Ireland.

Some highlights of the year include:

The outcomes of this two-year programme exceeded our expectations. It delivered a systematic, comprehensive, and effective approach in collaboration with both healthcare professionals and those affected by penile cancer.

Through the programme we reached men, partners, and healthcare professionals with vital information, helping to improve understanding, reduce stigma, and encourage earlier detection.

It is disappointing that we were unable to secure funding to further develop and continue the programme, but we are pleased that the two online support groups continue to run as part of the programme’s legacy.

29

Research Support for The Robert Lane Tissue Bank

Research is vital to understand why men develop prostate, testicular or penile cancer and to improve diagnosis and treatment.

Orchid was delighted to support the work carried out in The Robert Lane Tissue Bank (RLTB) led by Professor Dan Berney with a grant once again in the reporting year. THE RLTB holds over 9,000 male-specific cancer tissue samples to facilitate understanding of prostate, testicular and penile cancers, from the potential causes, through to how they are diagnosed, treated, and possibly prevented.

It also holds over 1,200 blood samples as part of an ongoing collaborative collection of circulating tumour cells (CTCs) which are used by Professor Yong-Jie Lu whose work Orchid has previously supported.

The Robert Lane Tissue Bank 1 October 2024 to 30 September 2025

The focus of the work in the RLTB is to translate basic research into practical treatments for patients with novel tests and bespoke predictive treatments. With limited funding support for the Tissue Bank and general financial challenge within the UK education sector which has caused all universities to cut cost in some way, the team worked hard and efficiently to keep the Robert Lane Tissue Bank running at a high standard to fulfil all the routine requirement and supporting research projects whenever required. Most importantly, they renewed the ethical approval for another five years and successfully (without any issues) passed UK National Human Tissue Act (HTA) audit, the first since the pandemic.

30

Testicular cancer Penile cancer Research The year ahead Governance Financial review

Highlights of the year

Research achievements of the year

Following the successful collaboration work of the team’s Trans-atlantic prostate group with Myriad, which produced a Food and Drug Administration (FDA) approved prostate cancer treatment stratification biomarker (gene panel) for early stage prostate cancer and several high impact publications, the team are in discussion with Myriad for another major collaboration study.

This would use the Trans-atlantic prostate group samples stored in the Tissue Bank and Professor Berney’s histopathology expertise to develop/train an AI pathology tool to assess prostate cancer prognosis using routinely stained pathological slides. The research contract/agreement has been drafted, and the team are waiting for the QMUL research office to review and sign off.

The team are delighted to announce a collaboration with the Institute of Cancer Research to collect samples of prostate cancer from three major radiotherapy clinical trials, funded by CRUK in February 2025.

The team completed all patient blood sample process including circulating tumour cell (CTC)

enumeration, plasma and white blood cell frozen storage for a large five-year research project aiming to using circulating tumour cells as biomarkers for treatment stratification of localised prostate cancer.

Linking to the above project and stored samples, the team applied for and was awarded a significant Prostate Cancer UK research grant to further investigate the combined value of CTCs, blood immune cell and factors and tumour cell DNA released into the blood (circulating tumour DNActDNA) to predict surgery outcome (post-surgery cancer recurrence).

89 hormone therapy resistance prostate cancer patient blood samples were collected for a project to develop blood biomarker(s) for an aggressive form of prostate cancer, called neuroendocrine prostate cancer. The biomarker is to predict the response of a novel therapy for neuroendocrine prostate cancer, which is under development at Open University.

26 age-matched healthy control and 22 untreated prostate cancer patient blood samples were collected for blood immune cell analysis and identified certain white blood subpopulations associated with prostate cancer potentially to be further developed for prostate cancer early detection.

Developed an AI software for automated CTC analysis.

Publications

Professor Berney has over 300 per reviewed publications, and numerous book chapters on urological pathology. He has an H score (a metric used to measure a researcher’s productivity, quality and citation impact) of 89 and his work has been cited 42,464 times. He contributed to 12 publications in this 12-month funding period.

Professor Lu has over 200 per reviewed publications and numerous book chapters on cancer genetics and biology. He has contributed to seven peerreviewed journal publications in the reporting year.

31

Professor Dan Berney

Professor Yong-Jie Lu

The research carried out in the RLTB was led by Professor Dan Berney who is an internationally recognised pathology expert in the three male genitourinary cancers. His reputation is such that he receives referrals nationally and internationally for his opinion. Professor Berney is co Editor of the new World Health Organisation classification of genitourinary cancers.

Furthermore, Professor Berney has helped to pioneer changes in the grading of prostate cancer, and two new tests to work out disease aggressiveness. In testis cancer he is helping refine decisions on adjuvant chemotherapy and treatment in early disease and has helped identify cases which are now known to be benign but were previously thought to be malignant.

Professor Lu is an international leader in prostate cancer genetics and circulating biomarker studies. He is the scientific lead on the Robert Lane Tissue Bank Governance Committee and has supervised the day-to-day running/maintenance in the past year while running his research team on prostate cancer circulating biomarker development.

Professor Lu is the Senior Editor of The American Journal of Cancer Research. He is also a member of the European Liquid Biopsy Society steering committee and the co-chair of the Circulating Tumour Cell Working Group.

Future funding and thank you to the Robert Lane Tissue Bank team

In recent years funding requests from Professor Berney to further work in the Robert Lane Tissue Bank have been reviewed and then approved mid-year. However, Trustees made the difficult decision not to offer a new grant towards the work of the Robert Lane Tissue Bank from the beginning of the new financial year which began on 1 October 2025.

This was not a decision taken lightly, but one which reflected the financial position Orchid found itself in as the year progressed.

Orchid is incredibly proud of our significant support for the work led by Professor Berney and Professor Lu over many years. As a small charity we were privileged to have been able to support a long and productive association with such innovative and impactful work which has been so important in improving understanding of male cancers both in and beyond the UK.

We use our Annual Report to formally thank Professor Berney, Professor Lu and all the team involved with the Robert Lane Tissue Bank, and to wish them well with their future research.

32

Testicular cancer Penile cancer Research The year ahead Governance Financial review

As well as supporting the Robert Lane Tissue Bank during the year, Orchid was also pleased to continue to support this research led by Dr Belinda Nedjai who is an Associate Professor (Reader) specialising in Cancer Biomarkers and Epigenetics.

Characterisation of the anaerobic microbiome and genomic methylation status of prostate cancer patients experiencing active Vitamin D and K2 deficiency: prevention, risk stratification, diagnosis and treatment potential.

Project summary

Prostate cancer is one of the most common malignancies in men; however, a substantial proportion of individuals with slow-growing disease ultimately die with prostate cancer rather than from it. Current clinical screening relies primarily on the prostate-specific antigen (PSA) blood test, followed by prostate biopsy when PSA levels are elevated. Although widely used, biopsy is invasive, uncomfortable, and limited in its ability to predict tumour aggressiveness. There is a critical need for non-invasive tools capable of distinguishing indolent from clinically significant prostate cancer to guide patient management, particularly for those on active surveillance.

Prostate MRI (Magnetic Resonance Imaging) has improved the detection of aggressive cancers, yet remains costly, operator-dependent, and imperfect. Emerging evidence suggests that the prostate microbiome may influence tumour biology. The research group’s recent Phase 1 findings indicated that obligate anaerobic bacteria are associated with increased PSA levels and heightened prostate

cancer risk. If specific microbial signatures—or their downstream molecular effects—can identify individuals likely to develop aggressive or recurrent disease, this could markedly improve risk stratification, reduce unnecessary biopsies, and ultimately save lives.

A key biological question remains unresolved: Do bacteria contribute causally to prostate carcinogenesis, or does a tumour microenvironment permit bacterial colonisation? The example of Helicobacter pylori and gastric cancer – once controversial yet now foundational to cancer prevention – suggests that microbiome-driven carcinogenesis is plausible. As ~90% of humanassociated microbial species are obligate anaerobes, and as hypoxic scar tissue commonly fosters microbial growth, similar mechanisms may operate in the prostate.

The team’s long-term vision is to develop a noninvasive urine-based biomarker that integrates microbiome composition with host DNA methylation profiles to improve surveillance and enable potential chemopreventive strategies.

33

The main research questions addressed by the team were:

Project deliverables (aims and objectives)

Part 1: Role of Anaerobic Bacteria in Prostate Cancer Aggressiveness

Background and objectives

Prostate cancer has been increasingly linked to microbial dysbiosis, particularly involving low-oxygentolerant species such as Cutibacterium acnes. Analogous to the well-established role of Helicobacter pylori in gastric cancer, specific bacteria may contribute to chronic inflammation and carcinogenesis within the prostate. Building on the team’s earlier work demonstrating that obligate anaerobes correlate with PSA elevation, they sought to identify which species are most strongly associated with biochemical markers of aggressiveness.

Methods

The team analysed post-digital-rectal-exam urine samples from 89 men with prostate cancer using 16S rDNA sequencing. Six previously implicated genera were targeted: Finegoldia, Fusobacterium, Prevotella, Peptoniphilus_A, Peptostreptococcus, and Veillonella_A. We additionally screened for novel taxa associated with PSA levels.

Results

Among the predefined taxa, Peptostreptococcus demonstrated a statistically significant association with elevated PSA. They also observed potential interactive effects between Prevotella and Fusobacterium, suggesting a synergistic microbial influence on inflammation or epithelial turnover. Notably, they identified an unexpected association with Ochrobactrum_A, an aerobic species, raising the possibility that microbial dynamics in prostate disease may be more complex than solely anaerobic colonisation.

Conclusions

These findings support a model in which obligate anaerobes – and potentially select aerobic bacteria – contribute to chronic inflammatory injury, raising PSA and potentially facilitating precancerous changes. Larger, longitudinal studies are needed to clarify causality and determine whether microbial signatures precede or follow disease initiation.

January 2025 saw the conclusions of the research published in a paper in Cancers which is an esteemed peer reviewed journal.

Part 2: Vitamin D Receptor (VDR) Methylation and Prostate Cancer Aggressiveness

Recent genomic methylation research indicates that chronic bacterial inflammation can alter epigenetic regulation of host genes, including those involved in Vitamin D signalling. Vitamin D, in conjunction with Vitamin K2, plays a recognised immunomodulatory and anticancer role; disruption of this pathway may facilitate tumour progression.

Methods and initial findings

Using in silico screening followed by analysis of their urine-derived DNA samples, Dr Nedjai and her team selected specific genes and CpG sites associated with VDR function for targeted methylome profiling. Preliminary results indicate differential methylation of VDR-related loci in patients with high PSA compared to those with lower PSA, suggesting that

34

Testicular cancer Penile cancer Research The year ahead Governance Financial review

microbial-induced inflammation may epigenetically impair Vitamin D-mediated tumour suppression.

These findings require validation in a larger cohort but strongly support integrating epigenetic and microbial data for biomarker development.

Beneficiaries

Primary beneficiaries:

Secondary beneficiaries:

Key outcomes and impact

Feedback and notable remarks

Orchid was proud to support published work which was positively received, with reviewers highlighting the novelty of linking anaerobic bacteria to prostate cancer risk. The project provides the first evidence supporting a bacterial contribution to disease progression in men on active surveillance, establishing a foundation for larger translational studies.

Dr. Belinda Nedjai

Dr. Belinda Nedjai is an Associate Professor (Reader) specialising in Cancer Biomarkers and Epigenetics. She also serves as the Director of the Molecular Epidemiology Laboratory within the Wolfson Institute of Population Health (WIPH).

Dr. Nedjai earned her Ph.D. in Functional Genomics from Queen Mary, Bart’s, and the London School of Medicine and Dentistry in London, UK. Her academic journey includes a Master’s degree in Cellular and Molecular Physiopathology from the University of Sciences, Pierre et Marie Curie, Paris VI, France, and another Master’s degree in Biochemistry with a focus on Immunology and Genetics from the University of Science, Aix Marseille II Luminy, France.

She conducted research for eight years at Imperial College London as post-doctoral researcher and then research Fellow. Her extensive experience spans over 20 years in identifying and validating biomarkers using advanced Next generation sequencing techniques. Her primary research focus is the application of novel quantitative technologies for discovery and validation of DNA methylation biomarkers.

One of Dr. Nedjai’s notable achievements is the development and validation of DNA methylation assays for triaging women infected with papillomavirus, such as the S5 classifier, which combines DNA methylation of HPV and human genes. This method has been substantially validated in studies worldwide and is considered a gold standard in the field of HPV-related cancers. Dr. Nedjai is currently involved in numerous studies focussing on the development of screening and triage molecular tools and algorithms to detect HPV related precancer lesions and cancer early.

She is dedicated to unravelling genetic and epigenetic pathways in HPV related cancers and working on the development of biomarkers for early cancer detection, accurate diagnosis, and effective cancer management.

Dr. Nedjai’s laboratory collaborates closely with clinicians, epidemiologists, and statisticians on various clinical trials, exploring innovative screening, diagnostic, and treatment approaches.

35

Welcome from the Trustees CEO’s letter The year in review Fundraising Prostate cancer

The year ahead

Orchid heads into the new financial year with a smaller staff team but just as committed to achieving the best possible outcomes for those at risk of or diagnosed with prostate, testicular or penile cancer. Work will be delivered in line with the four pillars of our strategy and fundraising will underpin everything we do...

36

Testicular cancer Penile cancer Research The year ahead Governance Financial review

Support

Orchid will continue to offer personal support for patients, families and healthcare professionals. We will promote these Nurse-led services so people from across the UK can find the support they need. We will continue to listen to patients and their loved ones, as well as to healthcare professionals working in the field. Any service development will be informed by these learnings.

With just one Male Cancer Nurse Specialist in post, the hours of Orchid’s Freephone Male Cancer Helpline, including our email service, have been reduced. There is however a procedure in place for callers to leave messages and to receive call backs. The opportunity remains for people calling our Helpline to be signposted to other services, such as Orchid’s telephone counselling service for those diagnosed with penile or testicular cancer, or peer support opportunities.

One legacy of the Four Nations Penile Cancer programme is that the online Wives, Husbands and Partners penile cancer support group will continue to meet and in the new year will be facilitated by an experienced counsellor working with Orchid Nurse Rob Cornes. Rob will continue to run the online support group for men living with and beyond penile cancer.

The Wives, Husbands and

Partners penile cancer support group will continue to meet and in the new year will be facilitated by an

experienced counsellor

Orchid Nurse Rob Cornes will also continue in his roles as a member of the European Association of Urology (EAU) Patient Advocacy Group and the

European Reference Network eUROGEN European Patient Advocacy Group where he represents both testicular and penile cancer on behalf of Orchid.

Supported by penile cancer patient advocates, he will continue to work to improve the patient experience across Europe for those affected by these two rare cancers. Plans for the year include attending the EAU Patient Advocacy Meeting in Lisbon where he will also be there as a core member of the BALANCE Study, which aims to improve understanding of how prostate cancer affects Black men of African and Caribbean ancestry, as well as men of mixed ethnic backgrounds worldwide.

Furthermore, he will facilitate a Penile Cancer Roundtable at the upcoming EAU Congress in London in March. This session will focus on the psychological impact of penile cancer and its effects on intimacy.

Awareness

Orchid’s education and awareness programme remains at the heart of our strategy because when cancer is found at an early stage, treatment is more likely to be successful. We will continue to raise awareness of prostate, testicular and penile cancer, mindful of the need to reach diverse and vulnerable groups to reduce health inequalities and ensuring our messaging reaches those who may not feel able to prioritise their health or who miss mainstream health messaging.

Male Cancer Information Roadshows will be delivered in targeted communities – most are delivered in areas of deprivation – as funding becomes available. We will also continue to offer male cancer talks and presentations to community groups and via our Health at Work programme. As the new year started, we were in the early stages of delivering an innovative male cancer awareness project (which also highlighted the importance of HPV vaccinations for boys) in faith settings across London.

We will continue to deliver the “Active Participation in Male Cancer Awareness in Prisons in England”

37

programme which started in August 2024. This work is funded by the National Lottery Community Fund and through it, Orchid offers a range of options to prisons across the country. Examples of project activities include talks with the opportunity for questions and answers, attendance at health days, and training prison residents as Male Cancer Community Champions.

We will deliver a series

of mini-campaigns

about each of the three

male-specific cancers and the support that Orchid

can offer

Digital activity has become increasingly important, and we will continue to use our social media platforms to reach both existing and new audiences with male cancer messaging and information about the support Orchid can offer. Our approach during the year will be to deliver mini campaigns about each of the three male-specific cancers and the support Orchid can offer. The first in this planned series will be around the theme of “When life turns upside down.”

Orchid’s Male Cancer Awareness Week will take place between 14–20 September 2026 with a focus on survivorship, with International Penile Cancer Awareness Day on 20 September 2026.

Research

Orchid’s roots are in male cancer research as research is vital to understand why men develop prostate, testicular or penile cancer and to improve diagnosis and treatment.

We are proud that the research Orchid has funded for more than 25 years, including the two areas

funded in 2024-2025, has led to significant advancements in male cancer diagnosis, treatment, and patient care.

With a drop in unrestricted income in the last year, Trustees made the difficult decision to focus Orchid’s funding in the coming year on delivering our Nurse-led support services and education and awareness programmes.

Orchid is therefore not planning to make research grants during the year, but will review this decision on an ongoing basis depending on income received.

Educate

Throughout the year our Nurse will review Orchid’s information on diagnosis, treatment and care in line with our scheduled review dates to ensure that it remains up to date.

Our Nurse will also promote our resources to, and work with, healthcare professionals to improve the patient journey for those affected by male cancer. We will work to build closer relationships with healthcare professionals such as urologists and pharmacists to disseminate information, as well as work with targeted corporate partners to spread male cancer messaging.

Furthermore, we will continue to work across England, Northern Ireland, Scotland and Wales to equip people with knowledge about the male cancer signs, symptoms, treatment and care options, targeting the most vulnerable and at-risk groups.

Fundraising underpins everything we do

Our fundraising strategy for the year will continue to focus on generating income from diverse income streams at the best possible return on investment to ensure the charity has sufficient funding in place to deliver our plans for the coming years, exploring new fundraising opportunities whenever possible.

Applications will be submitted to warm Charitable Trusts and Foundations on a rolling basis, carrying out

38

Testicular cancer Penile cancer Research The year ahead Governance Financial review

research to identify new prospects, reporting back to funders in a timely manner. We will continue to develop our events programme, as well as establish mutually beneficial partnerships with our corporate supporters to meet their needs as well as Orchid’s.

We know that Orchid’s work is only possible because of the generosity of our supporters, and we will look after them in every way we can. We will review our supporter care processes using ongoing learnings to ensure people have the best possible experience whilst giving to us and fundraising for us. Where possible we will continue to offer personalised support to all the individuals and community groups who support us with donations or fundraise on our behalf, our corporate partners, and the Charitable Trusts and Foundations who provide much needed grants.

Working in line with our Environmental Policy

Orchid is committed to reducing our carbon footprint and minimising our environmental impact. As part of our ongoing efforts, we continuously monitor our activities to align with our Environmental Policy.

environmental impact, all while ensuring that individuals still have easy access to the vital information and support they need.

Good governance

Orchid’s focussed group of Trustees are committed to working closely with Orchid’s CEO in the coming year to ensure Orchid operates efficiently, and that the charity is well run.

Thank you

We are grateful to everyone who contributed towards our work in the last year, as well as to those who will support us in the year ahead.

As the year began, the Orchid team was at the Royal Parks Half Marathon to cheer on our magnificent team of runners fundraising on our behalf and supporting other fundraising initiatives such as the plans for collections at the Punk Festivals in Morecambe.

Thank you to everyone who has previously supported us, and we are looking forward to supporting more wonderful fundraisers as the year progresses.

Encouraging digital

downloads over printed materials is helping us reduce paper waste, lowering postage costs,

and minimising our overall

environmental impact

One key initiative is optimising how we share resources. Encouraging digital downloads over printed materials is helping us reduce paper waste, lowering postage costs, and minimising our overall

39

Governance

Orchid’s aim is to provide greater knowledge and awareness about male specific cancers by funding scientific and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing information about them to people throughout the UK.

Objects, operating context and activities

Objects

The number of people being diagnosed with prostate, testicular or penile cancer in the UK has been increasing. There are now over 58,000 new cases of these cancers each year. Orchid’s aim is to provide greater knowledge and awareness about male specific cancers by funding integrated scientific and medical research into the prevention, diagnosis and treatment of these diseases, raising awareness, delivering Nurse-led services and providing eye-catching, easy to understand information about them to people throughout the UK, thereby helping to ensure a better quality of life for those affected.

Operating context and activities

Orchid's aim is to offer the best possible care and support for men and their families through awareness and education programmes, to promote better understanding of the signs and symptoms of these cancers, to encourage an early diagnosis and improved outcomes and to ensure the best possible care through our influence at a local and national level. Through funding world class research, our aim is to improve our understanding of male cancers, how they work, possible causes and to identify new treatments and enhance care. Support and information delivered by our Nurse Specialists and Community Engagement Team enables people interested in or affected by male cancers to have the best possible outcome.

40

Testicular cancer Penile cancer Research The year ahead Governance Financial review

Structure, governance and management

Duly registered as a Charity, Orchid is incorporated as a company, limited by guarantee, and governed by its Memorandum and Articles of Association.

Orchid recognises that an effective Board of Trustees with a balanced composition is essential if the charity is to be effective in achieving its objects.

Trustees conducted a comprehensive governance review using the template of the Charity Governance Code and the Charity Commission's governance recommendations. As a result, the Board underwent a planned consolidation, reducing its size to a focused group of Trustees to steer Orchid through the latter period of the year and beyond. We are now exploring how best to expand the Board to support the needs of our resized charity.

Orchid’s Trustee Recruitment and Training Policy was reviewed during the year. Applications from individuals seeking to become a Trustee will be considered as and when appropriate by the Board. Trustees acknowledge the need to increase diversity on the Board and continue to explore the best ways to do this.

The Board met six times during the year plus Orchid’s Annual General Meeting. Most meetings were held in person. At the AGM, as required by the constitution, one third of the Trustees (or the nearest number thereto) retire from office in rotation, in order of longevity of appointment and are eligible to be reappointed.

Trustee training and induction

New Trustees are offered an induction programme. All new Trustees receive a copy of Orchid’s governing documentation, the most recent Annual Report, and the Charity Commission’s The essential trustee: what you need to know, what you need to

do (CC3). New Trustees are also offered a meeting with the lead programme researchers and a visit to the research programmes. In the absence of in-house provision, or an otherwise formalised programme of training, the Chief Executive advises Trustees of opportunities that will increase their general understanding of voluntary sector, healthcare and/or medical research issues.

Opportunities for ongoing governance training are highlighted in the monthly updates the CEO provides for Trustees. Trustees can elect to attend courses which interest them or which they feel will benefit them in their role as an Orchid Trustee.

Delegation and decision-making

The decision-making process operates as follows:

41

Public benefit

The Trustees confirm that they have complied with the duty in section 17 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit (including PB2 Public Benefit: Running a Charity ).

Key management personnel and remuneration policy

Orchid is committed to attracting and retaining talented staff. Staff are kept fully informed of the organisation’s strategy and objectives, and individual performance is reviewed throughout the year. Learning and development remain a priority. Temporary and volunteer personnel are engaged for specific tasks to ensure a balanced approach to managing administration, awareness campaigns, support services and fundraising.

The key management personnel comprise the Trustees and the Chief Executive. Trustees do not receive remuneration. The salary of the Chief Executive is set by the Chairman of the Board of Trustees in consultation with the Finance Committee and Board of Trustees following an annual review of performance. The Charity uses Royal College of Nursing (RCN) bands, NHS pay scales and Charity Salary Surveys for benchmarking salaries of all other members of staff. Annual salary increases for staff are discussed and where applicable approved by the Finance Committee and Board of Trustees.

Research Programme: Peer Review

Given the importance of expert independent peer review in validating applications for new research grants and the verification of outcomes, a Scientific Advisory Board provides the Board of Trustees with the necessary degree of objectivity as to the quality, value for money and efficiency of research that the Charity currently funds or may consider funding.

Internal control and risk management

Orchid is committed to active management of risk. Risk management is incorporated into governance and management structures, planning processes and all aspects of service delivery. Orchid produces a risk register which identifies risk and allocates responsibility for managing areas of risk to named individuals. Following Charity Commission recommendations the risk register identifies risks under the following headings:

Each identified risk is assessed in terms of likelihood and impact and then weighted giving a gross risk rating. Actions to minimise each risk are identified and responsibility for monitoring these is given to named individuals. The strength of each risk management strategy is given a numeric rating enabling the net risk to be calculated.

The Chief Executive is responsible to the Board for the management and implementation of the risk management strategy and reports to the Board on progress towards mitigating each risk. Risk is reviewed quarterly by staff and not less than annually by the Finance Committee and Board of Trustees. They direct the Chief Executive as to the priorities and action to be taken to mitigate or remove them.

Several other policies, therefore, deal with risk management and risk assessment e.g. Health and Safety Policy, Safeguarding etc. All policies are reviewed annually and updated in line with changes in legislation, regulation and best practice. New policies are introduced as required.

42

Testicular cancer Penile cancer Research The year ahead Governance Financial review

Orchid’s Risk Register

Specific risks which, if materialised, would have had a significant impact on the Charity have been identified. These are as follows:

Governance and compliance

Ability to maintain a Board of Trustees with all the skills required to ensure that all aspects of governance are adhered to

Mitigation

Operational

Attracting, developing and retaining talented staff in a competitive employment market

Mitigation

Financial

Economic pressures, competition, fundraising regulatory environment and consumer behaviour changes leading to a significant fall in income

Mitigation

Research

Orchid’s Research Programme fails to deliver results

Mitigation

Environmental / external

Changes in government policy or budgets, Charity sector regulations, or reform of the NHS or changes to the research environment that negatively impact on Orchid’s work

Mitigation

Quality assurance

Patients, their families, health and social professionals, educators and other interested parties given inaccurate, poor quality information leading to reputational damage

Mitigation

43

Financial review

Results for the year

Income for the year ended 30 September 2025 totalled £729,636 (2024: £767,210). After total expenditure of £813,495 (2024: £1,047,335) the year’s activities show a net deficit of £83,859 (2024: deficit of £280,125). Total reserves at the end of the year amounted to £273,155 (2024: £357,014).

Reserves policy

Designated reserves are funds that have been earmarked by the Trustees for future expenditure on the objectives of the Charity, and at the end of the year the Trustees had designated £121,808 to help fund the costs of increased organisational capacity with the Charity. Free reserves are distinct from funds that have been earmarked or ‘designated’ for future expenditure on the objectives of the Charity, but for which legal liability has not yet been accepted. They must be maintained at a level which ensure the Charity’s core activity of funding research and awareness during a period of sustained unforeseen difficulty and a proportion must be in a readily realisable form. The calculation of the required level

of reserves is an integral part of the Charity’s planning, budgeting and forecast cycle. It should take into account:

The available free reserves net of tangible and intangible fixed assets are £94,199 (2024: £79,367). During the year the Trustees agreed to change the policy to maintain free reserves at a minimum of 9-12 months of operating costs from its previous level of 3-4 months. This decision was taken to ensure greater stability for the charity going forward with a stronger financial buffer and allow it to target a growth strategy with increased security. At current levels of expenditure this equates to £144,000 – £192,000. Whilst currently below our targeted reserves, throughout 2024–2025 Orchid introduced a number of cost saving measures which should lead to growth in reserves in the coming years and allow Orchid to return to achieving the targeted levels.

Formal statements Statement of Trustees’ responsibilities

The Trustees, who are also directors of Orchid Cancer Appeal for the purposes of company law, are responsible for preparing the Trustees’ Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice.)

Company law requires Trustees to prepare financial statements for each financial year which give a true and fair view of the state of the affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

44

Testicular cancer Penile cancer Research The year ahead Governance Financial review

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the Charity and financial information included on the Charity’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Independent Examiner’s information

So far as each of the directors at the time the Trustees’ report is approved is aware:

a) there is no relevant information of which the examiner is unaware; and

b) they have taken all relevant steps they ought to have taken to make themselves aware of any relevant independent examination information and to establish that the examiners are aware of that information.

The examiner, Moore Kingston Smith LLP, has been authorised for appointment in accordance with Section 485 of the Companies Act 2006.

Moore Kingston Smith LLP has indicated its willingness to continue in office and in accordance with the provisions of the Companies Act, it is proposed that it will be re-appointed examiner for the ensuing year.

The financial statements have been prepared in accordance with the provisions of the Companies Act 2006 Part 15 relating to small companies, the Statement of Recommended Practice applicable to charities preparing

their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP) and the Memorandum and Articles of Association of the Company.

Signed on behalf of the Trustees

W Cohen, Treasurer 16/06/26

45

Independent Examiner’s Report to the Trustees of Orchid Cancer Appeal

I report to the charity trustees on my examination of the accounts of the Company for the year ended 30 September 2025.

Responsibilities and basis of report

As the charity’s trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 (“the 2006 Act”).

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 (“the 2011 Act”). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145 (5) (b) of the 2011 Act.

Independent examiner’s statement

Since the Company’s gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Association of Chartered Certified Accountants which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

  1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or

  2. the accounts do not accord with those records; or

  3. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Adam Fullerton FCA DChA

Date:

For and on behalf of Moore Kingston Smith LLP Chartered Accountants 6th Floor, 9 Appold Street, London EC2A 2AP

  1. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or

46

Testicular cancer Penile cancer Research The year ahead Governance Financial review

Statement of financial activities

(incorporating an income and expenditure account) For the year ended 30 September 2025

Unrestricted
Note
Total
£
Income from:
Donations and Legacies
2
477,787
Charitable Activities
4
-
Trading Activities
369
Investment income
1,008
Total income
479,164
Expenditure on:
Raising funds
Fundraising
(donations and grants)
5
177,978
Charitable Activities
Education and Awareness
5
230,860
Research
5
60,776
Total expenditure
469,614
Net income / (expenditure) and
net movement in funds
5,6
9,550
Reconciliation of funds
Total funds brought forward
216,524
Total funds carried forward
226,074		 Restricted
30
Total
£
131,160
119,312
-
-
250,472
-
332,525
11,356
343,881
(93,409)
140,490
47,081		 Year ended
Year ended
September
30 September
2025
2024
£
£
608,947
624,545
119,312
140,344
369
419
1,008
1,902
729,636
767,210
177,978
196,759
563,385
616,847
72,132
233,729
813,495
1,047,335
(83,859)
(280,125)
357,014
637,139
273,155
357,014

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in Note 14 to the financial statements.

47

Balance sheet

As at 30 September 2025

Note
Fixed Assets
Tangible Assets 10
Intangible fixed assets 11
Current Assets
Cash at bank and in hand
Debtors 12
CREDITORS
Amounts due within one year 13
Net Current Assets
Total Assets less Current Liabilities15
NET ASSETS
Represented by:14
General Unrestricted Funds
Designated Funds
Restricted funds		 30 September 2025
£ £
1,984
8,083
337,253
159,248
496,501
(233,413)
263,088
273,155
273,155
104,266
121,808
226,074
47,081
273,155		 30 September 2024
£
£
3,225
12,125
526,386
157,187
683,573
(341,909)
341,664
357,014
357,014
94,717
121,808
216,525
140,489
357,014		 30 September 2024
£
£
3,225
12,125
526,386
157,187
683,573
(341,909)
341,664
357,014
357,014
94,717
121,808
216,525
140,489
357,014
341,664
357,014
357,014
216,525
140,489
357,014

The company is limited by guarantee.

For the year ending 30 September 2025 the charitable company was entitled to exemption from statutory audit under Section 477 of the Companies Act 2006 relating to small companies.

No notice from Trustees requiring an audit has been deposited under Section 476 of the Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and for the preparation of accounts.

The financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board and authorised for issue on 16 June 2026 and signed on its behalf by:

Mr W Cohen

Company number 03963360

48

Testicular cancer Penile cancer Research The year ahead Governance Financial review

Statement of cash flows For the year ended 30 September 2025

£
Cash flows from operating activities:
Net expenditure for the year
(83,859)
Adjustments for:
Depreciation charges
5,283
Interest
(1,008)
Decrease / (increase) in debtors
(2,061)
(Decrease) / increase in creditors
(108,496)
Net cash (used in) operating activities
Cash flows from investing activities:
Interest
1,008
Purchase of fixed asset
-
Net cash provided by investing activities
Change in cash and cash equivalents in the year
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year
Analysis of cash and cash equivalents
Cash at bank and in hand		 2025
£
(190,141)
1,008
(189,133)
526,386
337,253
337,253
337,253		 £
(280,125)
5,655
(1,902)
(89,230)
260,682
1,902
(1,499)		 2024
£
(104,920)
403
(104,517)
630,903
526,386
526,386
526,386

49

Notes to the financial statements

1. Accounting policies

For the year ended 30 September 2025

Basis of Preparation

These financial statements have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). The Charity is a public benefit entity for the purposes of FRS 102 and therefore has also prepared the financial statements in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (The FRS 102 Charities SORP), the Companies Act 2006 and the Charities Act 2011.

Going Concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements. The trustees have made this assessment in respect to a period of one year from the date of approval of these financial statements. In particular the trustees have considered the charities forecasts and projections and have taken account of pressures on donation income. After making enquiries the trustees have concluded there is a degree of uncertainty around donation income for 2025/26 and beyond, however that there is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. The charity therefore continues to adopt the going concern basis in preparing its financial statements.

Functional Currency

The functional currency is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity operates. The financial statements are also presented in pounds sterling, rounded to the nearest £1.

Taxation

The Charity has suffered no tax charge as it is not subject to UK Corporation tax on its charitable activities.

Depreciation

Depreciation is provided at the following annual rates so as to write off the cost of each asset over its useful life. Assets with a purchase consideration in excess of £1,000 are capitalised.

Computer and Office Equipment - 33[1] ⁄ 3% on written down value.

Intangible fixed assets

Intangible fixed assets are included in the balance sheet at original cost less accumulated amortisation. Amortisation is provided on a straight line basis calculated to write down the cost of all intangible assets to their estimated residual values over the number of years of expected use.

Website - 20% on straight line value.

Funds Accounting

General funds are unrestricted funds available for use at the discretion of the Trustees in furtherance of the general activities of the Charity and which have not been designated for other purposes.

Designated funds comprise funds which have been set aside at the discretion of the Trustees for specific purposes.

Restricted funds are funds subject to specific restrictions imposed by donors or by the nature of the appeal. The purpose and use of the Charity’s restricted funds is set out in the notes to the financial statements.

Income

Income becoming available to the Charity is recognised when there is entitlement to the income, probability of receipt and amounts can be measured reliably as per FRS102 SORP.

Gifts in kind are valued and brought in as income and the appropriate expenditure, when the items are used/distributed. The values attributable to gifts in kind are an estimate of the gross value to the organisation, where quantifiable. Where this intangible income relates to project activities, it is included as an activity in furtherance of the Charity's objects.

Expenditure

Cost of raising funds includes costs associated with the fund-raising events in furtherance of the Charity’s objects.

Charitable expenditure includes costs associated with particular activities in furtherance of the Charity’s objects.

Governance costs are those incurred in connection with the management of the Charity’s assets, organisational administration, and compliance with constitutional and statutory requirements and are included within support costs.

Charitable expenditure comprises direct expenditure including direct staff costs attributable to the activity. Support costs which cannot be directly attributed to an activity have been allocated to activities on a basis consistent with use of the resources.

Grants payable are charged when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attached are fulfilled. Grants offered subject to conditions which have not been met at the balance sheet date are noted as a commitment, but not accrued as expenditure

50

Testicular cancer Penile cancer Research The year ahead Governance Financial review

Financial Instruments

The charitable company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ of FRS 102 to all of its financial instruments. Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. With the exceptions of prepayments, deferred income and amounts owed to or from HMRC. All other debtor and creditor balances are considered to be basic financial instruments under FRS 102.

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Pension Scheme

The Charity operates a defined contribution stakeholder pension scheme. The amount charged to the statement of financial activities in respect of pension costs is the Charity's contributions payable in the year. The assets of the scheme are held separately from the Charity. There was no outstanding liability owed to the scheme at the end of the current or prior years.

Employee Benefits

The cost of short-term employee benefits are recognised as a liability and an expense. The cost of any material unused holiday entitlement is recognised in the period in which the employee’s services are received.

Critical accounting estimates and areas of judgement

In the view of the Trustees in applying the accounting policies adopted, no judgements were required that have significant effect on the amounts recognised in the financial statements nor do any estimates or assumptions carry a significant risk of material adjustment in the next financial year.

Cash and Cash equivalents

Cash and cash equivalents in the balance sheet comprise cash at banks and in hand and term deposits with an original maturity date of three months or less. For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined above.

Creditors

Short term trade creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method. Deferred income represents grants, contract funding and training fees relating to future periods.

51

2. Donations

Current year

Current year
Individuals
Legacies
Corporates
Trusts and Foundations
Fundraising Events
Other
Total
Prior year
Individuals
Legacies
Corporates
Trusts and Foundations
Fundraising Events
Total		 Restricted
£
-
-
-
131,160
-
-
131,160
Restricted
£
1,360
-
-
155,284
-
156,644		 Year ended
Year ended
30 September 2025
30 September 2024
Unrestricted
Total
Total
£
£
£
138,970
138,970
157,321
92,157
92,157
-
67,410
67,410
91,226
20,914
152,074
205,134
158,336
158,336
170,864
-
-
-
477,787
608,947
624,545
Year ended
30 September 2024
Unrestricted
Total
£
£
155,961
157,321
-
-
91,226
91,226
49,850
205,134
170,864
170,864
467,901
624,545		 Year ended
Year ended
30 September 2025
30 September 2024
Unrestricted
Total
Total
£
£
£
138,970
138,970
157,321
92,157
92,157
-
67,410
67,410
91,226
20,914
152,074
205,134
158,336
158,336
170,864
-
-
-
477,787
608,947
624,545
Year ended
30 September 2024
Unrestricted
Total
£
£
155,961
157,321
-
-
91,226
91,226
49,850
205,134
170,864
170,864
467,901
624,545
624,545

52

Testicular cancer Penile cancer Research The year ahead Governance Financial review

3. Fundraising events

Current year

Current year
Cycling events
Running events
Third party organised events
Trek
Other
Total
Prior year
Cycling events
Running events
Third party organised events
Trek
Other
Total		 Restricted

£
-
-
-
-
-
-
Restricted

£
-
-
-
-
-		 Year ended
Year ended
30 September 2025
30 September 2024
Unrestricted
Total
Total
£
£
£
1,646
1,646
9,253
120,988
120,988
57,014
33,813
33,813
99,324
-
-
-
1,889
1,889
5,273
158,336
158,336
170,864
Year ended
30 September 2024
Unrestricted
Total
£
£
9,253
9,253
57,014
57,014
99,324
99,324
-
-
5,273
5,273
170,864
170,864

4. Charitable activities

Current year
Big Lottery Community Fund
Total
Prior year
Big Lottery Community Fund
Total		 Restricted

£
119,312
119,312
Restricted

£
140,344
140,344		 Year ended
Year ended
30 September 2025
30 September 2024
Unrestricted
Total
Total
£
£
£
-
119,312
140,344
-
119,312
140,344
Year ended
30 September 2024
Unrestricted
Total
£
£
-
140,344
-
140,344

53

5. Total expenditure

Cost of
Education and
raising funds
Awareness
£
£
Grants
-
-
Staff costs
80,105
187,690
Fundraising expenses
64,923
-
Information materials
-
257,211
Direct costs
-
33,719
145,028
478,620
Support costs
Depreciation
1,380
3,631
Other
21,800
57,351
Governance - staff costs
6,680
15,653
Governance -
independent examiners
3,090
8,130
32,950
84,765
Total expenditure
177,978
563,385
Prior year
196,759
616,847		 Year ended
Year ended
30 September 2025
30 September 2024
Research
Total
Total
£
£
£
60,009
60,009
205,428
8,590
276,386
302,609
-
64,923
60,767
-
257,211
293,692
-
33,719
27,196
68,599
692,248
889,692
148
5,159
5,655
2,338
81,489
121,354
716
23,049
21,734
331
11,551
8,900
3,533
121,248
157,643
72,132
813,496
1,047,335
233,729
1,047,335		 Year ended
Year ended
30 September 2025
30 September 2024
Research
Total
Total
£
£
£
60,009
60,009
205,428
8,590
276,386
302,609
-
64,923
60,767
-
257,211
293,692
-
33,719
27,196
68,599
692,248
889,692
148
5,159
5,655
2,338
81,489
121,354
716
23,049
21,734
331
11,551
8,900
3,533
121,248
157,643
72,132
813,496
1,047,335
233,729
1,047,335
889,692
5,655
121,354
21,734
8,900
157,643
1,047,335

6. Grants awarded

Year ended Year ended
30 September 2025 30 September 2024
Total Total
£ £
Grant commitments brought forward 236,892 35,646
Institutional grants for medical research awarded during year/period
– Orchid Study and Travel Awards (2024: 2 individuals, 2023: 2 individuals) - 1,128
– Barts and London School of Medicine - 54,398
– Research Innovation Project - 149,902
– Robert Lane Tissue Bank 60,009 -
Payments made during period/year (112,277) (4,182)
Grant commitments carried forward 184,624 236,892
Payable less than one year 184,624 236,892
Payable two to five years - -

54

Testicular cancer Penile cancer Research The year ahead Governance Financial review

7. Net expenditure for the period

Year ended Year ended
This is stated after charging: 30 September 2025 30 September 2024
Total Total
£ £
Depreciation 1,242 1,613
Independent examiners’ remuneration:
Independent examination 5,985 5,700
Trustees’ remuneration Nil Nil

8. Staff costs and numbers

8. Staff costs and numbers
Year ended Year ended
Staff costs were as follows: 30 September 2025 30 September 2024
Total Total
£ £

Salaries and wages		 262,747 269,204
Social security costs 18,162 22,772
Pension contributions 3,317 3,307
284,226 295,283

Consultant costs		 15,209 29,060

Total cost		 299,435 324,343

During the year ended 30 September 2025 1 employee earned more than £60,000 (Year to 30 September 2024:1). The pension contribution paid in respect of these employees totalled £Nil (2024: £Nil)

The pension contribution paid in respect of this employee totalled £Nil (2023: £Nil)

The key management personnel of the charity comprise the trustees and the chief executive.

The charity trustees do not receive remuneration.

The total remuneration of the chief executive was £89,169 (year ended 30 September 2024: £86,324).

The number of employees whose emoluments amounted to over £60,000 in the year (exclusive of employer pensions and employer National Insurance contributions) was as follows:

2025 2024
No. No.
£60,000–£69,999 - -
£70,000–£79,999 1 1

The average number of employees during the year was 8.3 (2024: 7.4)

The average number of employees during the year on a headcount basis was as follows:

Fundraising
Governance
Education and Awareness
Grant support

Overall average		 2025
No.
2.6
0.4
5.2
0.1
8.3		 2024
No.
1.7

0.0
5.4
0.3
7.4

55

9. Taxation

The charitable company is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

10. Tangible fixed assets

10. Tangible fixed assets
Computer and
30
office equipment
£
Cost
At the start of the period
12,423
Additions
-
Disposals
-

At the end of the period
12,423

Depreciation
At the start of the period
9,198
Charge for Period
1,241
Disposals
-

At the end of the period
10,439

Net book value
At the end of the period
1,984

At the start of the period
3,225		 September
30 September
2025 total
2024 total
£
£
12,423
10,924
-
1,499
-
-
12,423
12,423
9,198
7,584
1,241
1,614
-
-
10,439
9,198

1,984
3,225
3,225
3,341
September
30 September
2025 total
2024 total
£
£
20,208
20,208
-
-
-
-
20,208
20,208
8,083
4,042
4,042
4,041
-
-
12,125
8,083

8,083
12,125
12,125
16,166
11. Intangible fixed assets
Website
30
development
Cost
At the start of the period
20,208
Additions
-
Disposals
-

At the end of the period
20,208

Amortisation
At the start of the period
8,083
Charge for Period
4,042
Disposals
-

At the end of the period
12,125

Net book value

At the end of the period
8,083

At the start of the period
12,125

56

Testicular cancer Penile cancer Research The year ahead Governance Financial review

12. Debtors

12. Debtors
Year ended Year ended
30 September 2025 30 September 2024
Total Total
£ £
Prepayments 26,330 69,476
Other debtors and accrued income 132,918 87,711
159,248 157,187

13. Creditors: amounts due within one year

Grants Payable
Trade and Other Creditors
Accruals
 Year ended
Year ended
30 September 2025
30 September 2024
Total
Total
£
£
184,624
236,892
6,537
62,976
42,252
42,041
233,413
341,909		 Year ended
Year ended
30 September 2025
30 September 2024
Total
Total
£
£
184,624
236,892
6,537
62,976
42,252
42,041
233,413
341,909		 Year ended
Year ended
30 September 2025
30 September 2024
Total
Total
£
£
184,624
236,892
6,537
62,976
42,252
42,041
233,413
341,909
14. Movements in funds
Brought forward
£
Unrestricted
General
94,716
Designated – Development
121,808
Total unrestricted
216,524
Restricted
Counselling
-
Awards for All
-
Faith
-
Education and Awareness
1,000
Four Nations Penile Cancer Programme
59,355
Penile Cancer Peer Support
805
Student Study and Travel Scholarships
2,729
The National Lottery Community Fund:
Overcoming the Barriers
-
The National Lottery Community Fund:
Active Participation in Male Cancer
Awareness in Prisons
51,085
Nurse Led Services
16,500
Roadshows
860
Robert Lane Tissue Bank
8,156
Total restricted
140,490
Total funds
357,014		 Income
£
479,164
-
479,164
-
20,000
15,000
14,100
5,000
-
7,500
-
119,312
20,250
46,110
3,200
250,472
729,636		 Expenditure
£
(469,614)
-
(469,614)
(4,500)
(20,000)
(5,875)
(13,100)
(59,355)
(805)
(10,229)
-
(139,441)
(32,250)
(46,970)
(11,356)
(343,881)
(813,495)		 Transfers
Carried forward
£
£
-
104,266
-
121,808
-
226,074
4,500
-
-
-
9,125
-
2,000
5,000
-
-
-
-
-
-
-
30,956
(4,500)
-
-
-
-
-
-
47,081
-
273,155

57

14. Movements in funds (continued)

Prior year movements in funds
Brought forward
£
Unrestricted
General
176,793
Designated – Research
-
Designated – Development
121,808
Designated – Awareness
-
Total unrestricted
298,601
Restricted
Counselling
-
The National Lottery Community Fund:
Overcoming the Barriers
29,030
The National Lottery Community Fund:
Active Participation in Male Cancer
Awareness in Prisons
-
The Innovation Research Project
156,137
Penile Cancer Peer Support
1,565
Education and Awareness
4,000
Student Study and Travel Scholarships
3,729
Roadshows
-
Robert Lane Tissue Bank
13,054
Nurse Led Services
2,000
Four Nations Penile Cancer Programme
129,023
Total restricted
338,538
Total funds
637,139		 Income
£
470,222
-
-
-
470,222
-
81,629
58,715
500
2,484
22,500
-
50,160
49,500
31,500
-
296,988
767,210		 Expenditure
£
(552,299)
-
-
-
(552,299)
-
(110,659)
(7,630)
(156,637)
(3,244)
(25,500)
(1,000)
(49,300)
(54,398)
(17,000)
(69,668)
(495,036)
(1,047,335)		 Transfers
Carried forward
£
£
-
94,716
-
-
-
121,808
-
-
-
216,524
-
-
-
-
-
51,085
-
-
-
805
-
1,000
-
2,729
-
860
-
8,156
-
16,500
-
59,355
-
140,490
-
357,014		 Transfers
Carried forward
£
£
-
94,716
-
-
-
121,808
-
-
-
216,524
-
-
-
-
-
51,085
-
-
-
805
-
1,000
-
2,729
-
860
-
8,156
-
16,500
-
59,355
-
140,490
-
357,014
-
-
51,085
-
805
1,000
2,729
860
8,156
16,500
59,355
140,490
357,014

General funds are unrestricted funds available for use at the Trustees’ discretion in furtherance of the general activities of the charity and which have not been designated for other purpose

Designated Development funds represent monies set aside at the Trustees’ discretion to be used to help fund the costs related to increasing the organisational capacity of the charity.

58

Testicular cancer Penile cancer Research The year ahead Governance Financial review

15. Analysis of net assets between funds

Unrestricted
funds
£
Fixed Assets
10,067
Current Assets
449,420
Creditors due within one year
(233,413)
Net assets at 30 September 2025
226,074
Prior year analysis of net assets between funds
Unrestricted
funds
£
Fixed Assets
15,350
Current Assets
543,082
Creditors due within one year
(341,908)
Net assets at 30 September 2024
216,524		 Restricted
Total funds at
funds
30 September 2025
£
£
-
10,067
47,081
496,501
-
(233,413)
47,081
273,155
Restricted
Total funds at
funds
30 September 2024
£
£
-
15,350
140,490
683,572
-
(341,908)
140,490
357,014		 Restricted
Total funds at
funds
30 September 2025
£
£
-
10,067
47,081
496,501
-
(233,413)
47,081
273,155
Restricted
Total funds at
funds
30 September 2024
£
£
-
15,350
140,490
683,572
-
(341,908)
140,490
357,014
357,014

16. Related party transactions

Aggregate donations of £nil were received from trustees in the year ended 30 September 2025. (Year to 30 September 2024: £50,000)

17. Financial commitments

For the year ended 30 September 2025, the charity was committed to making the following future payments under non cancellable operating leases.

Year ended Year ended
30 September 2025 30 September 2024
Total Total
Land and buildings £ £
Expiring within one year 15,637 15,637
Expiring within two to five years - -
15,637 15,637

18. Capital commitments

At the year ended 30 September 2025, the charity had no capital commitments.

59

60 Gray’s Inn Road, London WC1X 8AQ Tel 020 3745 7310 www.orchid-cancer.co.uk

Registered in England with the Charity Commission No.1080540 Company Limited by Guarantee Registered in England No. 03963360